Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (NASDAQ: NKTX) is a clinical-stage biotechnology and biopharmaceutical company developing engineered natural killer (NK) cell therapies, with a stated focus on allogeneic, off-the-shelf NK cell therapies for autoimmune diseases. The NKTX news page on Stock Titan aggregates company press releases and market-moving updates so readers can follow how Nkarta’s NK cell platform and clinical programs progress over time.
Nkarta’s news flow frequently centers on clinical milestones for its lead candidate NKX019, including enrollment updates, protocol amendments, and dose-escalation decisions in the Ntrust-1 and Ntrust-2 autoimmune disease trials. The company also issues releases on investigator-sponsored trials of NKX019 in generalized myasthenia gravis and systemic lupus erythematosus, as well as presentations of clinical and preclinical data at scientific meetings such as rheumatology conferences.
Investors and observers can also find quarterly financial results and corporate highlights in Nkarta’s news, which summarize research and development spending, general and administrative expenses, net loss, and the company’s stated cash runway. These updates often include commentary on restructuring efforts, leadership changes in clinical and research roles, and Nkarta’s plans for future data disclosures from its NKX019 programs.
In addition, Nkarta regularly announces participation in healthcare and investor conferences, where management discusses the company’s NK cell platform, autoimmune focus, and clinical strategy. For anyone tracking NKTX stock, this news page offers a centralized view of Nkarta’s scientific, clinical, financial, and corporate developments related to its engineered NK cell therapies.
Nkarta (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.
The company will engage in a fireside chat scheduled for April 8, 2025, at 11:00 a.m. ET. Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website. The presentation recording will remain available on www.nkartatx.com for approximately 90 days following the event.
Nkarta (NKTX) reported its Q4 and full year 2024 financial results, announcing a significant restructuring including a 34% workforce reduction (53 positions) to extend cash runway. The company ended 2024 with a cash balance of $380.5 million, now expected to fund operations into 2029.
For FY2024, Nkarta reported a net loss of $108.8 million ($1.60 per share), with R&D expenses of $96.7 million and G&A expenses of $31.5 million. The restructuring is expected to cost $5.5-6.5 million in cash payments.
The company's development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in autoimmune conditions. Initial data from the Ntrust-1 and Ntrust-2 trials is expected in H2 2025. The executive leadership team will be reduced by over 50% as part of the restructuring efforts.
Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies, has announced its upcoming participation in two major investor conferences in March 2025.
The company will be featured in fireside chat sessions at the:
- TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 3:10 p.m. ET
- Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 3:00 p.m. ET
Investors and interested parties can access simultaneous webcasts of both events through Nkarta's website at www.nkartatx.com. Recordings will remain available on the company's Investors section for approximately 90 days after the events.
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in myasthenia gravis patients.
The treatment protocol involves administering NKX019 on Days 0, 3, and 7 following lymphodepletion with cyclophosphamide. The therapy aims to provide a safe, accessible treatment option for autoimmune diseases through B-cell depletion, potentially enabling long-term remissions via immune system reset.
Patient dosing has begun in both Ntrust-1 and the IST for systemic lupus erythematosus, with preliminary data from Ntrust-1 and Ntrust-2 expected in 2025.
Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the 7th Annual Evercore HealthCONx Conference. The company will participate in a fireside chat scheduled for December 4, 2024, at 2:10 p.m. ET.
The event will be accessible through a live webcast on Nkarta's website investor section, with a replay available for approximately 90 days following the presentation.
Nkarta (Nasdaq: NKTX), a company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the Stifel 2024 Healthcare Conference. The company will participate in a fireside chat scheduled for November 19, 2024, at 10:55 a.m. ET. The event will be webcast live on Nkarta's website investor section, with a replay available for approximately 90 days afterward.
Nkarta (NKTX) reported Q3 2024 financial results and corporate updates. The company has initiated patient dosing in both Ntrust-1 and investigator-sponsored trials of NKX019 for autoimmune diseases. Cash position stands at $405.3 million, expected to fund operations into late 2027. The company reported a net loss of $28.3 million ($0.39 per share) for Q3. Notably, Nkarta has decided to discontinue NKX019 development in lymphoma to focus on autoimmune diseases. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials is planned for 2025.
Nkarta, a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, at 12:30 p.m. ET, featuring a fireside chat.
Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website (www.nkartatx.com). For those unable to attend live, a replay of the webcast will be archived on the website for approximately 90 days. This conference participation provides an opportunity for Nkarta to showcase its progress and engage with the investment community.
Nkarta Inc. (NKTX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Enrollment in Ntrust-2, a second clinical trial of NKX019 for autoimmune diseases (systemic sclerosis, myositis, vasculitis), expected to start by year-end 2024.
2. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials planned for 2025.
3. Cash balance of $426.7 million as of June 30, 2024, expected to fund operations into late 2027.
4. Investigator-sponsored trial of NKX019 in systemic lupus erythematosus initiated at Columbia University.
5. Encouraging results from NKX019 retreatment in non-Hodgkin lymphoma patients.
6. Q2 2024 net loss of $25.0 million, or $0.34 per share.
7. R&D expenses were $23.1 million, and G&A expenses were $7.6 million for Q2 2024.
Nkarta Inc. (Nasdaq: NKTX) reported its Q2 2024 financial results and corporate highlights. Key points include:
1. Enrollment in Ntrust-2, a second clinical trial of NKX019 for autoimmune diseases, is expected to start by year-end 2024.
2. Preliminary clinical data from Ntrust-1 and Ntrust-2 trials planned for 2025.
3. Cash balance of $426.7 million as of June 30, 2024, expected to fund operations into late 2027.
4. Q2 2024 net loss of $25.0 million, or $0.34 per share.
5. R&D expenses were $23.1 million, while G&A expenses were $7.6 million for Q2 2024.
6. Nkarta presented follow-up data from its Phase 1 NKX019 trial in NHL, showing promising results in retreated patients.
7. Leadership updates include new President and Chief Medical Officer appointments.